online electronic cash Top See results about

Deputy Director Huang Huabo attended the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group. On December 12, 2024, the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group was held in Beijing. Huang Huabo, chairman of the working group, member of the party group and deputy director of the National Health Insurance Bureau, attended and spoke. The symposium summarized the work results of the National Working Group on Medical Security Standardization in 2024, and discussed the work in 2025, the five-year development plan of medical security standardization, the framework system and relevant medical insurance standards. Huang Huabo pointed out that in 2024, with the guidance of the National Standards Committee and the support of the bureau party group, all the work of the working group was smoothly promoted through the joint efforts of all members and relevant units inside and outside the bureau. In 2025, the high-quality development of medical insurance put forward higher requirements for medical insurance standardization. It is necessary to further strengthen the sense of responsibility, professionalism and cooperation, accelerate the construction of medical insurance standardization team, and play a supporting role for the high-quality development of medical insurance. (National Medical Insurance Bureau)On the 13th, glass fell by 2.14%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract glass closed at 2505, up or down by -2.14%, with a turnover of 671,300 lots. The position data showed that the top 20 seats were clear, and the difference position was 46,081 lots. The total turnover of glass futures contracts was 999,900 lots, an increase of 189,100 lots over the previous day. The first 20 seats in the contract held 565,600 lots, a decrease of 12,000 lots from the previous day. The short positions in the top 20 seats of the contract were 661,500 lots, a decrease of 13,600 lots from the previous day. (Sina Futures)Nigeria: About 130,000 members of Boko Haram have surrendered in the past five months. Christopher Moussa, chief of staff of Nigeria's defense, said on the 12th that nearly 130,000 members of the extremist organization Boko Haram have surrendered in the past five months. Moussa, attending the African Security Watch Conference in Doha, Qatar, said that from July 10th to December 9th, a total of 30,426 Boko Haram militants, 36,774 women and 62,265 children members of the organization surrendered. (Xinhua News Agency)

Ge Yu, former assistant general manager of China Xinbao Shandong Branch, was examined and investigated. The website of the State Supervision Committee of the Central Commission for Discipline Inspection reported on December 13th that according to the news of the Discipline Inspection and Supervision Team of the State Supervision Committee of the Central Commission for Discipline Inspection in China Export Credit Insurance Company and the Supervision Committee of Liaoning Provincial Commission for Discipline Inspection, Ge Yu, former member of the Party Committee and assistant general manager of Shandong Branch of China Export Credit Insurance Company, was suspected of serious violation of discipline and law. At present, he is being examined by the Discipline Inspection and Supervision Team of the State Supervision Committee of the Central Commission for Discipline Inspection in China Export Credit Insurance Company and supervised by the Supervision Committee of Dandong City, Liaoning Province.Goldman Sachs lowered the UK's GDP growth forecast for 2024 from the previous 1.2% to 1.0%.Puli Pharmaceutical Co., Ltd.: It won the bid for the tenth batch of national centralized drug procurement. According to Puli Pharmaceutical, on December 12, Puli Pharmaceutical's meglumine gadolinium tetate injection (trade name: Puli Yingxian) and Posaconazole injection (trade name: Puli Posa) both won the bid for the tenth batch of national centralized drug procurement.

Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Zaks, managing director of the European Central Bank: If necessary, the interest rate can be greatly reduced. zaks, managing director of the European Central Bank, said that if economic development requires it, the interest rate cut may be increased. Although zaks thinks that the gradual approach is appropriate, he warns that the impact of geopolitics and war may bring "new impetus" to inflation. Kazakhstan said in a blog post on Friday: "If necessary, this range can be greater than 0.25%." "The current method-analysis/decision based on data and each meeting-is very suitable for this situation." Zaks also said that the future trend of interest rates is also very clear, that is, downward. The neutral interest rate is closer to 2% than 3%, so it is still necessary to cut interest rates sharply.Puli Pharmaceutical Co., Ltd.: It won the bid for the tenth batch of national centralized drug procurement. According to Puli Pharmaceutical, on December 12, Puli Pharmaceutical's meglumine gadolinium tetate injection (trade name: Puli Yingxian) and Posaconazole injection (trade name: Puli Posa) both won the bid for the tenth batch of national centralized drug procurement.